Enzyvant Receives 2022 Rare Impact Industry Innovation Award from the National Organization for Rare Disorders (NORD) for Novel, Tissue-Based Therapy to Treat Ultra-Rare, Life-Threatening Pediatric Condition
Company honored for its work on RETHYMIC® (allogeneic processed thymus tissue-agdc), a one-time, treatment for…